65results about How to "Improve pathological damage" patented technology

The invention relates to the field of Chinese medicaments, in particular to a Chinese medicinal composition for preventing and treating ischemic brain injury, and a preparation method thereof. The Chinese medicinal composition for preventing and treating ischemic brain injury is an orally taken preparation prepared from extracts of raw astragalus roots, panax notoginseng, kudzuvine roots, baikal skullcap roots and gardenia serving as main active components, as well as pharmaceutical auxiliary materials. The preparation has obvious therapeutic effects on cerebral infarction convalescent symptoms of which the clinical manifestations are eye-mouth distortion, glossolalia, slobbering or hemiplegia, dark red tongue or yellow greasy tongue coating, weak or uneven pulse and the like.

The invention discloses application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines. The bifidobacterium adolescentis CCFM1061 can be rapidly colonized in the intestinal tracts, can remarkably improve fasting blood glucose and oral glucose tolerance of type 2 diabetes induced by STZ and high-fat diet and decrease the area under a curvewhen glucose tolerance is reduced, can remarkably alleviate the increase of total cholesterol and the decrease of high-density lipoprotein cholesterol in serum of the type 2 diabetes caused by STZ and high-fat diet, can remarkably alleviate the insulin resistance of the type 2 diabetes, can remarkably improve the level of inflammation in liver tissues of the type 2 diabetes, and can remarkably alleviate the pathological damage of the pancreas, liver and other tissues of the type 2 diabetes. In addition, the bifidobacterium adolescentis CCFM1061 has strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving PFOA toxicity.

The invention discloses a new use of notoginsenoside R1 in the preparation of medicines for preventing and/or treating the inflammatory diseases of the digestive system or healthcare foods as an active component. Experiment results show that the notoginsenoside R1 has an inhibition effect on the NF-kappa B signal pathway, and has substantial prevention and treatment effects on the NF-kappa B signal pathway mediated ulcerative colonitis, so the notoginsenoside R1 can be developed to medicines for preventing and/or treating the inflammatory diseases of the digestive system or healthcare foods. The new use urges the notoginsenoside R1 to fully perform its medicinal values, and is very important for researching and applying Panax Notoginseng.

The present invention belongs to the field of medicinal chemistry, and particularly relates to a bicyclol-based derivative and a pharmaceutically acceptable salt thereof, a preparation method of the bicyclol-based derivative, and applications of the bicyclol-based derivative in preparation of drugs for prevention and/or treatment of liver diseases and the like. The formula I is defined in the specification.

The invention discloses application of oxyberberine in preparation of a medicament for treating ulcerative colitis. The research of the invention finds that: the oxyberberine can safely and effectively resist ulcerative colitis, and comprises the following effects: remarkably improving general symptoms of ulcerative colitis mice, improving pathological injury, reducing the level of colon tissue inflammatory cytokines and immunoglobulins in serum, and increasing expression of tight junction proteins (TJs) in colon tissues. The drug effect of the oxyberberine for preventing and treating the ulcerative colitis is equivalent to that of azathiopurine of a traditional first-line treatment drug, and is superior to that of berberine. In addition, the oxyberberine has high safety, and the daily application dosage of the oxyberberine is not strictly limited in terms of safety and can be adjusted according to clinical actual conditions during use, so that better curative effect is ensured. The invention provides a better new drug choice for clinically treating ulcerative colitis, and the oxyberberine has good application prospect for clinical treatment of ulcerative colitis.

The invention provides an application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury. Furthermore, the histone deacetylase HDAC 6 is Tubastatin A. The selective inhibitor of HDAC 6 can lighten the renal pathology damage of acute kidney injury induced by cis-platinum and improve the kidney function. The HDAC6 inhibitor TA can lower the release of inflammatory factors and lighten the oxidative stress reaction through regulating an AKT signal access, an NF-KB inflammation access, an autophagy level and an E-cadherin expression; thus the apoptosis of kidney tubule cell and necrosis of tubule expansion are reduced, the renal pathology damage and kidney function are improved; the inhibitor can protect the kidney structure and function in the acute kidney injury. Therefore, HDAC6 is likely to be an important target point to prevent and treat the acute kidney injury.

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 25-35 parts of astragalus membranaceus, 15-25 parts of cordyceps cicadae, 8-12 parts of taxus chinensis, 1-5 parts of saffron, 10-15 parts of Chinese wolfberry, 10-20 parts of lucid ganoderma, 15-25 parts of radix puerariae, 15-25 parts of gynostemma pentaphylla, 10-20 parts of wine-treated rhubarb and 3-9 parts of liquorice. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has a very good protection effect on the kidney of a rat with diabetic nephropathy,and can effectively reduce kidney weight index, blood sugar, serum creatinine and urea nitrogen, reduce proteinuria and improve pathological injury of kidney tissues of the rat with diabetic nephropathy. According to the application disclosed by the invention, the effects of reducing proteinuria and protecting kidneys are achieved by down-regulating the expression of TGF-beta1, p-Smad2, p-Smad3 and alpha-SMA proteins in kidney tissues of DN rats.

The invention discloses a compound for treating pneumonia and application thereof, and relates to the technical field of medicines. The compound for treating pneumonia is a heterocyclic compound, a pharmaceutically acceptable salt of the heterocyclic compound and/or a pharmaceutically acceptable carrier of the heterocyclic compound. The compound for treating pneumonia has a significant improvementeffect on bacterial pneumonia, viral pneumonia, fungal pneumonia, immune pneumonia, mycoplasma pneumonia, chlamydia pneumonia and other pathogen pneumonia, and especially can significantly improve pathological damage of viral bacterial pneumonia. The heterocyclic compound involved in the compound for treating pneumonia is simple in synthesis method, is suitable for industrial production, and is more stable than natural analogues; the activity of the compound is remarkably superior to that of ribavirin, oseltamivir, cefazolin and penicillin G which are clinically first-line medicines, and theactivity of the compound is also remarkably superior to that of purine analogues A, B and C.

The invention discloses a new application of isorhamnetin, and the new application means that isorhamnetin is taken as an active component for preparation of medicaments or health food for treating enteritis. Research results show that: isorhamnetin is capable of obviously improving symptoms such as body weight loss, bloody stools, colon shortening and tissue pathological damage and the like of ulcerative colitis mice, and inhibiting expression of colon tissue inflammatory cytokines TNF-alpha and IL-6. Therefore isorhamnetin can be taken as the active component expected to be developed as the medicaments or health food for treating enteritis, and especially is expected to be developed as medicaments or health food for treating ulcerative colitis.

The invention relates to the technical field of medicine, and especially relates to a use of dencichine. The invention discloses the use of dencichine, prodrugs and pharmaceutical salts or plant extracts containing dencichine in preparation of drugs or health-care products for prevention or treatment of ulcerative colitis. The dencichine disclosed for the first time can significantly improve the experimental ulcerative colitis mice weight reduction, bloody stool, shortening of colon, tissue pathological damage and other symptoms, provides a new choice for clinical treatment of ulcerative colitis, and has a good application prospect.

The invention discloses an application of a TRPV4 ion channel as a drug target in organophosphorus compound poisoning. A medicine is a TRPV4 inhibitor. The medicine comprises: pharmacological antagonists of TRPV4 including GSK2193874, HC-067047, GSK205, GSK3395879, RN-1734 and GSK2798745, a blocking type antibody of the TRPV4, siRNA of the TRPV4 and the like. The important point of the invention is that the TRPV4 is found to be closely related to brain injury caused by the organophosphorus compound poisoning; and the TRPV4 antagonists or the siRNA inhibits intracellular calcium flow caused bythe organophosphorus compound poisoning and NMDA receptor-mediated excitatory toxicity, so that the nervous system toxic effect induced by poisoning of two organophosphorus compounds including oxophosphorus and soman is remarkably reduced at both in-vivo and in-vitro levels. Therefore, the invention provides a new drug target for prevention and treatment of the organophosphorus compound poisoning,and provides a new strategy for clinical treatment of the organophosphorus compound poisoning.

The invention discloses a bifidobacterium bifidum capable of reducing colon pathological injury and relieving constipation, and belongs to the field of microorganisms. The bifidobacterium bifidum CCFM1165 provided by the invention can effectively improve the first black stool time, the intestinal tract propulsion rate, the stool water content and the pathological damage of colon tissues of a constipation mouse. The strain provided by the invention can influence the content of excitement type and inhibition type gastrointestinal active peptides, and mainly increases the content of two short-chain fatty acids, so that the constipation symptom is relieved. Meanwhile, the bifidobacterium bifidum can effectively increase the abundance of bifidobacteria in excrement and can also relieve pathological damage of colon tissue, so that the effect of comprehensively relieving constipation diseases is achieved. In addition, compared with GDMCC NO.60939, the content of MTL in serum is better increased, secretion of 5-HT in colon tissue is promoted, and the propelling effect on small intestine peristalsis is more remarkable, so the GDMCC NO.60939 can be applied to disease control in a more targeted mode.

The invention belongs to the field of pharmacy and particularly relates to use of a DNA-dependent protein kinase specific inhibitor in the preparation of drugs to prevent and treat renal fibrosis. Furthermore, the DNA-dependent protein kinase activity inhibitor is NU7441. The DNA-PK activity inhibitor herein is a DNA-PK catalytic subunit selective inhibitor, which helps relieve renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction, and improve the renal functionality. The NU7441 inhibitor can inhibit DNA-PK activation specifically so as to inhibit abnormal activation ofmTOR, inhibit the epithelial-mesenchymal transition of renal tubular epithelial cells, inhibit the collagen generation of renal tubular epithelial cells and mesenchymal fibroblasts under TGF-beta 1 stimulation, improve renal pathological injury and renal function, and improve renal tubulointerstitial fibrosis. The effective clinical drugs to prevent and treat renal fibrosis-related diseases are provided herein.

The invention discloses application of bicyclol as shown in the formula (I) to preparation of a drug for treating and/or preventing diabetes.

The invention discloses a use of a hypoxia-inducible factor prolyl hydroxylase activity inhibitor in the preparation of a drug for preventing and treating acute kidney injury. The HIF prolyl hydroxylase activity inhibitor is Roxadustat (FG-4592). The HIF prolyl hydroxylase activity inhibitor is an HIF family selective inhibitor, and can alleviate pathological damages of cisplatin-induced acute kidney injury to kidneys and improve the functions of the kidneys. The FG-4592 can reduce apoptosis of renal tubular cells and renal tubular functions, improve the pathological injury and renal functionsof the kidneys and protect the structures and the functions of the kidneys in the acute kidney injury by activating HIF1alpha, promoting the expression of EPO and HO-1, inhibit apoptosis and down-regulate the release of inflammatory factors. The FG-4592 is currently in a Phase III clinical research stage in the field of prevention and treatment of chronic renal anemia, and it is found that the FG-4592 is highly possible to provide the effective clinical drug for preventing and treating the AKI.

The invention discloses an application of phloretin to preparation of an ulcerative colitis preventing and treating drug. According to the application of phloretin to the ulcerative colitis preventingand treating drug, the phloretin can prevent and treat ulcerative colitis, has no adverse reactions or side effects and has a maintained effect.

The invention discloses a lactobacillus mucoase for relieving endotoxin infection and application, and belongs to the technical field of microorganisms. The lactobacillus mucoase CCFM1142 capable of relieving endotoxin infection is obtained by screening through a large number of experiments, and the strain can reduce the content of proinflammatory factors in host blood infected by endotoxin, increase the concentration of anti-inflammatory factors and stabilize intestinal flora composition. By further investigating the application of the strain in food and drug combinations, experiments show that the food or drug containing the lactobacillus mucoase CCFM1142 can be used for preparing foods or drugs for preventing and/or treating endotoxin infection, and has a wide application prospect.

The invention discloses pediococcus pentosaceus antagonistic to escherichia coli O157: H7 and application of the pediococcus pentosaceus antagonistic to escherichia coli O157: H7. The pediococcus pentosaceus is pediococcus pentosaceus IM96 and is preserved in the Guangdong Microbial Culture Collection Center on May 17, 2021, with an accession number being GDMCC NO: 61654. Viable bacteria and fermentation supernatant of the pediococcus pentosaceus have good antibacterial activity, and especially have strong antagonistic activity on escherichia coli O157: H7 in vitro and in vivo. In addition, the pediococcus pentosaceus has good tolerance to gastrointestinal fluid, is high in safety, and can relieve and improve intestinal pathological injury, intestinal inflammation and intestinal epithelial barrier injury caused by escherichia coli O157: H7 in vivo. The pediococcus pentosaceus can be used for preparing medicines, food or food additives, animal feeds and microbial preparations with antibacterial activity in the future, and has good application prospects.

The invention discloses a medicine for preventing and/or treating alcoholic intestinal injury, and belongs to the technical field of microorganisms and medicines. The invention provides a medicine forpreventing and/or treating alcoholic intestinal injury or alcoholic liver injury. The effective component of the medicine is lactobacillus helveticus CCFM1121, and the effective component of the medicine is lactobacillus helveticus CCFM1121. The lactobacillus helveticus CCFM1121 can effectively relieve alcoholic intestinal injury and alcoholic liver injury, and is specifically embodied in that (1) the mRNA expression quantity of intestinal tight junction protein of an alcohol modeling mouse is remarkably increased; (2) the content of endotoxin (LPS) in serum of alcohol modeling mice is remarkably reduced; (3) the activity of glutamic-pyruvic transaminase (ALT) and glutamic oxalacetic transaminase (AST) in serum of alcohol modeling mice is remarkably reduced; and (4) the pathological injury of the liver tissue of the alcohol modeling mouse is obviously improved.

The invention discloses a drug for treating renal-deficiency humid-heat type chronic nephritis. The drug is prepared from the following material medicines in parts by weight: 20-40 parts of astragalus membranaceus, 8-12 parts of white atractylodes rhizome, 8-12 parts of pulp of dogwood fruit, 10-30 parts of eucommia ulmoides, 10-20 parts of rhizoma alismatis, 10-30 parts of herba pyrrosiae, 10-30 parts of oldenlandia diffusa and 3-7 parts of pseudo-ginseng. After being proved by a pharmacological experiment, the drug disclosed by the invention has a better function in treating chronic nephritis, is safe to take, suitable for preventing and treating chronic nephritis. The invention further discloses a preparation method and an application of the drug.

The invention discloses a product capable of regulating CYP1A1 gene expression, and belongs to the technical field of microorganisms. The invention provides a product, the effective component of the product is Lactobacillus plantarum CCFM8661, and the Lactobacillus plantarum CCFM8661 can effectively regulone the human body CYP1A1 gene expression, which is specifically reflected in thon (1) ponhological damage of benzopyrene exposed mouse colonic tissue is significantly improved; (2) the mRNA expression level of the CYP1A1 gene in the colon of the mouse exposed by benzopyrene is remarkably improved, so that the product provided by the invention has an extremely high application prospect in regulating the expression of the CYP1A1 gene of a human body and improving the intestinal health of the human body.

The invention relates to the technical field of medicine, and especially relates to a use of orientin. The invention discloses the use of orientin, prodrugs and pharmaceutical salts or plant extracts containing orientin in preparation of drugs or health-care products for prevention or treatment of ulcerative colitis. The orientin disclosed for the first time can significantly improve the experimental ulcerative colitis mice bloody stool, shortening of colon, tissue pathological damage and other symptoms, provides a new choice for clinical treatment of ulcerative colitis, and has a good application prospect.